PDCD1 and non-small cell lung carcinoma: Recently, immunotherapy with immune-checkpoint inhibitors (ICIs) has achieved impressive success and anti-programmed cell death-1 (PD-1)/anti-programmed cell death ligand-1 (PD-L1) inhibitors have been approved by the United States Food and Drug Administration for the treatment of advanced NSCLC.